Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 3, Pages 509
Publisher
MDPI AG
Online
2021-01-29
DOI
10.3390/cancers13030509
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element
- (2020) Steven Kregel et al. NUCLEIC ACIDS RESEARCH
- Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
- (2020) Xinzhe Yu et al. MOLECULAR CELL
- Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
- (2020) Carmen A. Banuelos et al. Cancers
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC resistant to Second-Line Antiandrogen Therapy
- (2020) Geun Taek Lee et al. MOLECULAR CANCER THERAPEUTICS
- Alternative (backdoor) androgen production and masculinization in the human fetus
- (2019) Peter J. O’Shaughnessy et al. PLOS BIOLOGY
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
- (2019) Tatsuo Sugawara et al. INTERNATIONAL JOURNAL OF CANCER
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
- (2019) Suriyan Ponnusamy et al. CLINICAL CANCER RESEARCH
- Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease
- (2019) Alba Jiménez-Panizo et al. ENDOCRINE-RELATED CANCER
- A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
- (2018) Stephanie Guillaumier et al. EUROPEAN UROLOGY
- Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy
- (2018) Nisha M Badders et al. NATURE MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
- (2018) Howard I. Scher et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Metastatic Prostate Carcinoma from Imperial Rome (1st to 2nd Centuries AD)
- (2018) Simona Minozzi et al. PATHOBIOLOGY
- Diversity of Quaternary Structures Regulates Nuclear Receptor Activities
- (2018) Pablo Fuentes-Prior et al. TRENDS IN BIOCHEMICAL SCIENCES
- Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
- (2018) Yasuomi Shimizu et al. Journal of Clinical Medicine
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- Structure of the homodimeric androgen receptor ligand-binding domain
- (2017) Marta Nadal et al. Nature Communications
- Genetically tunable frustration controls allostery in an intrinsically disordered transcription factor
- (2017) Jing Li et al. eLife
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
- (2016) Eva De Mol et al. ACS Chemical Biology
- Backbone 1H, 15N, 13C NMR assignment of the 518–627 fragment of the androgen receptor encompassing N-terminal and DNA binding domains
- (2016) Sandra Meyer et al. Biomolecular NMR Assignments
- Sequence Context Influences the Structure and Aggregation Behavior of a PolyQ Tract
- (2016) Bahareh Eftekharzadeh et al. BIOPHYSICAL JOURNAL
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Neoadjuvant Enzalutamide Prior to Prostatectomy
- (2016) Bruce Montgomery et al. CLINICAL CANCER RESEARCH
- Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
- (2016) Carmen A. Banuelos et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation
- (2016) Nada Lallous et al. MOLECULAR CANCER THERAPEUTICS
- DNA binding triggers tetramerization of the glucocorticoid receptor in live cells
- (2016) Diego M. Presman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies
- (2016) Kamyar Ghabili et al. UROLOGY
- Galeterone for the treatment of advanced prostate cancer: the evidence to date
- (2016) Emmanuel Antonarakis et al. Drug Design Development and Therapy
- Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
- (2015) Jeffrey L. Gustafson et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer
- (2015) Daniel P. Petrylak et al. INVESTIGATIONAL NEW DRUGS
- AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
- (2015) A. Omlin et al. INVESTIGATIONAL NEW DRUGS
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
- (2015) Andrew K. Kwegyir-Afful et al. Oncotarget
- EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
- (2015) Lucas J. Brand et al. Oncotarget
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Engineered repressors are potent inhibitors of androgen receptor activity
- (2015) Greg N. Brooke et al. Oncotarget
- Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
- (2014) Maria Thadani-Mulero et al. CANCER RESEARCH
- Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
- (2014) Ravi S.N. Munuganti et al. CHEMISTRY & BIOLOGY
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells
- (2014) William C. Krause et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor
- (2014) Huifang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy
- (2014) Sarah K. Martin et al. Molecular Oncology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor uses relaxed response element stringency for selective chromatin binding and transcriptional regulation in vivo
- (2014) Biswajyoti Sahu et al. NUCLEIC ACIDS RESEARCH
- Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
- (2014) Carmen A. Banuelos et al. PLoS One
- Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium
- (2013) Minyoung Lim et al. ACS Chemical Biology
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Mini-review: Foldosome regulation of androgen receptor action in prostate cancer
- (2013) Laia Querol Cano et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
- (2013) S. A. Loddick et al. MOLECULAR CANCER THERAPEUTICS
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Backdoor pathway for dihydrotestosterone biosynthesis: Implications for normal and abnormal human sex development
- (2012) Maki Fukami et al. DEVELOPMENTAL DYNAMICS
- Allosteric Modulators of Steroid Hormone Receptors: Structural Dynamics and Gene Regulation
- (2012) Raj Kumar et al. ENDOCRINE REVIEWS
- A role for selective androgen response elements in the development of the epididymis and the androgen control of the 5α reductase II gene
- (2012) Stefanie Kerkhofs et al. FASEB JOURNAL
- The androgen receptor gene mutations database: 2012 update
- (2012) Bruce Gottlieb et al. HUMAN MUTATION
- Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer
- (2012) Vikash Reebye et al. MOLECULAR ENDOCRINOLOGY
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- Niphatenones, Glycerol Ethers from the Sponge Niphates digitalis Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity
- (2011) Labros G. Meimetis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.
- (2011) Nathan A. Lack et al. JOURNAL OF MEDICINAL CHEMISTRY
- A conserved surface on the ligand binding domain of nuclear receptors for allosteric control
- (2011) Víctor Buzón et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
- (2011) Iain J. McEwan Molecular BioSystems
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Prostate metastatic bone cancer in an Egyptian Ptolemaic mummy, a proposed radiological diagnosis
- (2011) Carlos Prates et al. International Journal of Paleopathology
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- An androgenic steroid delivery vector that imparts activity to a non-conventional platinum(ii) metallo-drug
- (2010) Martin Huxley et al. DALTON TRANSACTIONS
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- History of prostate cancer treatment
- (2009) Seshadri Sriprasad et al. SURGICAL ONCOLOGY-OXFORD
- Structural Characterization of the Native NH2-Terminal Transactivation Domain of the Human Androgen Receptor: A Collapsed Disordered Conformation Underlies Structural Plasticity and Protein-Induced Folding†
- (2008) Derek N. Lavery et al. BIOCHEMISTRY
- Structural basis for the nuclear import of the human androgen receptor
- (2008) M. L. Cutress et al. JOURNAL OF CELL SCIENCE
- Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain
- (2008) Philippa Davies et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
- (2008) A Rodriguez-Gonzalez et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More